Prime Medicine (NASDAQ:PRME) Shares Gap Up – Still a Buy?

Shares of Prime Medicine, Inc. (NASDAQ:PRME) gapped up prior to trading on Thursday . The stock had previously closed at $3.83, but opened at $3.99. Prime Medicine shares last traded at $3.7310, with a volume of 615,638 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PRME shares. Lifesci Capital raised Prime Medicine to a “strong-buy” rating in a research report on Monday, March 2nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Prime Medicine in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy”.

Prime Medicine Stock Down 3.3%

The stock has a market cap of $668.94 million, a P/E ratio of -2.75 and a beta of 2.56. The stock’s fifty day moving average price is $3.86.

About Prime Medicine

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.